Atg-010
Indolent B-Cell Non-Hodgkin Lymphoma
Explore 38 assets in Indolent B-Cell Non-Hodgkin Lymphoma →Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Antengene Corporation
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
25Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05265975CT.gov A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Indolent B-Cell Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Atg-010 (this asset) | Antengene Corporation | P1/2 | C · 39 |
| Fludarabine | Institute of Hematology & Blood Diseases Hospital, China | P3 | BB |
| Cyclophosphamide | Institute of Hematology & Blood Diseases Hospital, China | P2 | BB |
| Rituximab | Fox Chase Cancer Center | P3 | BB |
| Pembrolizumab | University of Washington | P2 | BB |
| Vaccin Genhevac B Pasteur | Central Hospital, Nancy, France | P4 | BB |
| Ibrutinib | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P3 | BB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BB |
| Acalabrutinib | Emory University | P2 | BB |
+42 more in the Indolent B-Cell Non-Hodgkin Lymphoma cohort
Other indications for Atg-010
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | P2 | CCC · 49 |
| Plasma Cell Myeloma | — | P2 | CC · 45 |
| Diffuse Large B-Cell Lymphoma | — | P1/2 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Atg-010 in Indolent B-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/atg-010-indolent-b-cell-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →